Company Active LTD

Company profile

Skygazer Labs Ltd

Home Page - mySymptoms Food Diary & Symptom Tracker

Skygazer Labs Ltd is a UK company with status active founded in 2010 based in East of England.

CRN
07287061
Founded
2010
Age
16

Overview

Legal name
SKYGAZER LABS LTD
Region
East of England
Registered address
CAMBRIDGE HOUSE CAMBORO BUSINESS PARK
GIRTON
CAMBRIDGE
CAMBRIDGESHIRE
ENGLAND
CB3 0QH
Insolvency history
No

Latest accounts

Financial period: 1 Jul 2023 to 30 Jun 2024

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
2

Company events

Reference milestones and recent Companies House filing stream events.

9 events
31 Mar
2027

Accounts due

Accounts Due

Next accounts due date

27 Mar
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

27 Mar
2026

Accounts With Accounts Type Micro Entity

Accounts Analysed

AA | Transaction MzUxMjkzNTM0OWFkaXF6a2N4

Published 27 Mar 2026 09:33

13 Mar
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Jun
2025

Accounts filed

Accounts

Last accounts made up date

07 Aug
2024

Change To A Person With Significant Control

Persons-with-significant-control

PSC04 | Transaction MzQzMTUyMjg0NmFkaXF6a2N4

Published 07 Aug 2024 16:19

07 Aug
2024

Change To A Person With Significant Control

Persons-with-significant-control

PSC04 | Transaction MzQzMTUyMjg0NWFkaXF6a2N4

Published 07 Aug 2024 16:19

07 Aug
2024

Change To A Person With Significant Control

Persons-with-significant-control

PSC04 | Transaction MzQzMTUyMjg0MWFkaXF6a2N4

Published 07 Aug 2024 16:19

17 Jun
2010

Incorporated

Inception

Company registered at Companies House

Public funding

1 award
First funded
2022
Funded years
2022
Age at first award
12 years

Projects

2022 Grant for R&D Lead participant

mySymptoms Digital Therapeutic

1 Nov 2022 to 30 Apr 2023

Awarded
£49,375
Total cost £49,375

Almost 1 billion people suffer from Irritable Bowel Syndrome (IBS) with it affecting approximately 11% of the global population and 17% of the UK population. IBS symptoms cause a reduction in the quality of life for many sufferers, along with a significant cost burden to both the NHS and to employers from lost productivity. Our vision is to provide patien...

Product types

Grant for R&D